Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising geriatric population and concern for pain management
3.2.1.2 Increasing awareness of the risks associated with opioid use
3.2.1.3 Expanding research funding and activities
3.2.1.4 Growing advancements in the drug delivery system
3.2.2 Industry pitfalls & challenges
3.2.2.1 Side effects and safety concerns
3.2.2.2 Availability of alternative therapies and non-pharmacological approaches
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Nonsteroidal anti-inflammatory drugs (NSAIDs)
5.3 Local anesthetics
5.4 Antidepressants
5.5 Anticonvulsants
5.6 Analgesics
5.7 Other drug classes
Chapter 6 Market Estimates and Forecast, By Medication Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Over-the-counter (OTC)
6.3 Prescription
Chapter 7 Market Estimates and Forecast, By Indication, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Neuropathic pain
7.3 Post-operative pain
7.4 Chronic back pain
7.5 Cancer pain
7.6 Migraine
7.7 Arthritic pain
7.8 Muscle sprain/strain
7.9 Other indications
Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Oral
8.3 Topical
8.4 Injectable
8.5 Other routes of administration
Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 Hospital pharmacies
9.3 Retail pharmacies
9.4 Online pharmacies
Chapter 10 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Netherlands
10.3.7 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest of Latin America
10.6 Middle East and Africa
10.6.1 Saudi Arabia
10.6.2 South Africa
10.6.3 UAE
10.6.4 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 Amgen Inc.
11.2 Almatica Pharma LLC
11.3 Eli Lilly and Company
11.4 Fresenius Kabi AG
11.5 GlaxoSmithKline plc
11.6 Haleon group
11.7 Heron Therapeutics
11.8 Hyloris Pharmaceuticals
11.9 Johnson & Johnson Consumer Inc.
11.10 Neumentum Inc.
11.11 Novartis AG
11.12 Par Pharmaceutical, Inc.
11.13 Pfizer Inc.
11.14 Sanofi
11.15 Scilex Holding Company
11.16 Sun Pharmaceutical Industries Ltd.
11.17 Vertex Pharmaceuticals
11.18 WEX Pharmaceuticals Inc.
